This study, sponsored by Emory University, investigates the relationship between inflammation-induced changes in CNS glutamate levels and cognitive/behavioral symptoms in breast cancer patients undergoing chemotherapy. Given that approximately 70% of these patients experience cognitive dysfunction, there is a significant market opportunity for therapeutic interventions targeting these symptoms. The findings could inform the development of adjunctive therapies aimed at mitigating cognitive side effects, potentially enhancing patient quality of life and adherence to cancer treatment regimens. The collaboration with the National Institute of Mental Health (NIMH) may enhance credibility and facilitate future funding opportunities. Competitive implications include the potential for differentiation in a market where cognitive dysfunction in cancer patients is increasingly recognized but under-addressed.